| 王庆强,王立蓉,王立玮,左凌云,殷艳天.长期拉米夫定治疗乙肝后肝硬化患者血清肝纤维化指标、血小板以及超声影像学指标的变化[J].,2017,17(29):5701-5704 |
| 长期拉米夫定治疗乙肝后肝硬化患者血清肝纤维化指标、血小板以及超声影像学指标的变化 |
| Changes of Serum Liver Fibrosis Markers, Platelet Parameters and Ultrasound Imaging in Patients with Hepatitis B Cirrhosis after Long-term Lamivudine Therapy |
| 投稿时间：2017-03-06 修订日期：2017-03-30 |
| DOI：10.13241/j.cnki.pmb.2017.29.023 |
| 中文关键词: 乙肝肝硬化 拉米夫定 肝纤维化指标 血小板参数 超声影像学 |
| 英文关键词: Hepatitis B cirrhosis Lamivudine Hepatic fibrosis index Platelet parameters Ultrasonic imaging |
| 基金项目:江苏省科技计划项目（JS2015126) |
|
| 摘要点击次数: 129 |
| 全文下载次数: 98 |
| 中文摘要: |
| 摘要 目的：探讨长期拉米夫定治疗乙肝后肝硬化患者血清肝纤维化指标、血小板参数以及超声影像学相关指标的变化。方法：选取符合标准的108例乙肝肝硬化患者作为研究对象，依据随机数据表法将其分为对照组和观察组（均54例）；对照组患者常规降酶、护肝利胆等治疗，观察组在对照组的基础上给予口服拉米夫定治疗，观察3年。比较两组患者治疗前后血清肝纤维化指标（ⅣC、HA、PⅢP和LN）、血小板参数（PLT、PCT、MPV和PDW）以及超声影像学相关指标（肝左外叶体积/全肝体积，肝体积/脾体积、PVP和DMPV）。结果：治疗前，两组患者的上述指标比较，差异无统计学意义（P>0.05）；治疗后，两组的ⅣC、HA、PⅢP、LN、MPV、PDW、肝左外叶体积/全肝体积和DMPV水平，与组内治疗前相比，均显著下降，且观察组明显低于对照组，比较均有统计学差异（P<0.05）；两组的PLT、PCT、肝体积/脾体积和PVP水平较组内治疗前均显著升高，且观察组明显高于对照组（P<0.05）。结论：拉米夫定长期治疗乙肝后肝硬化可改善患者的血清肝纤维化指标、血小板参数以及超声影像学指标水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the changes of serum hepatic fibrosis index, platelet parameters and related indexes in pa- tients with hepatitis B cirrhosis after long-term lamivudine therapy. Methods: 108 patients with hepatitis B cirrhosis were selected as the research object, and were randomly divided into control group (n=54) and observation group (n=54); The control group was given con- ventional treatment such as reducing enzyme, liver and gallbladder, on the basis of control group, the observation group was given oral lamivudine treatment, observation of 3 years. Comparison of serum liver fibrosis indexes(ⅣC, HA, PⅢP and LN), platelet parameters (PLT, PCT, MPV and PDW) and ultrasound imaging index(left lateral liver volume / total liver volume, Liver volume / spleen volume, PVP and DMPV). Results: Before treatment, Comparison of the two groups of the above indicators, there was no significant difference between the two groups (P>0.05); After treatment, the two group IV C, HA, PⅢP, LN, MPV, PDW, left lateral liver volume / total liver volume and the level of DMPV, compared with the group before treatment were significantly decreased, and the observation group was significantly lower than the control group, there were statistically significant differences(P<0.05); Two groups of PLT, PCT, liver volume / spleen volume and PVP levels were significantly higher than those before treatment, and the observation group was significantly higher than the control group(P<0.05). Conclusion: Long term lamivudine therapy can improve the patient's serum liver fibrosis index, platelet parameters and the level of ultrasound imaging. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
